# US 2006/0078976 A1 · Crystal structures of bacterial thymidylate kinases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0078976 A1
- Document ID: US20060078976A1
- Status: Published application
- Kind: A1
- Application number: 11/123,166
- Filed: 2005-05-05
- Published: 2006-04-13
- Earliest claimed: 2002-11-05
- Assignees: Affinium Pharmaceuticals, Inc.
- Inventors: Aled Edwards; Akil Dharamsi; Masoud Vedadi; Teresa Clarke; Matthew Kimber
- Web page: https://patentgrep.com/patent/US20060078976A1

## CPC

- C12N 9/1229: {Phosphotransferases with a phosphate group as acceptor (2.7.4)}
- C12Y 207/04009: dTMP kinase (2.7.4.9)
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to novel drug targets for pathogenic bacteria. Accordingly, the invention provides purified protein comprising the amino acid sequence set forth in SEQ ID NO: 8. The invention also provides biochemical and biophysical characteristics of the polypeptides of the invention.

## Claims

### Claim 1

A composition comprising an isolated, recombinant polypeptide, wherein the polypeptide comprises: (a) an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; (b) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; or (c) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 1 or SEQ ID NO: 3 and has at least one biological activity of thymidylate kinase from E. faecalis; and wherein the polypeptide of (a), (b) or (c) is at least about 90% pure in a sample of the composition.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the polypeptide is at least about 95% pure as determined by gel electrophoresis.

### Claim 3 (depends on 1)

The composition of claim 1, wherein at least about two-thirds of the polypeptide in the sample is soluble.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the polypeptide is fused to at least one heterologous polypeptide that increases the solubility or stability of the polypeptide.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition is crystallized.

### Claim 6 (depends on 5)

The crystallized composition of claim 5, further comprising a co-factor.

### Claim 7 (depends on 5)

The crystallized composition of claim 5, further comprising a small molecule.

### Claim 8 (depends on 5)

The crystallized composition of claim 5, which diffracts x-rays to a resolution of about 3.5 Å or better.

### Claim 9 (depends on 5)

The crystallized composition of claim 5, wherein the crystallized composition has a monoclinic space group P21.

### Claim 10 (depends on 5)

A method for obtaining structural information of a polypeptide, the method comprising:
preparing a crystallized composition of claim 5 capable of diffracting X-rays to a resolution of 3.5 Å or better; and
analyzing the crystallized composition by X-ray diffraction to determine the three-dimensional structure of at least a portion of the polypeptide comprising said composition.

### Claim 11 (depends on 10)

The method of claim 10, wherein the crystallized composition further comprises a small organic molecule.

### Claim 12 (depends on 5)

A method for identifying a druggable region of a polypeptide, the method comprising:
(a) obtaining a crystallized composition of claim 5, such that the three-dimensional structure of the polypeptide in the composition may be determined to a resolution of 3.5 Å or better;
(b) determining the three-dimensional structure of the polypeptide using X-ray diffraction; and
(c) identifying a druggable region of the polypeptide based on the three-dimensional structure of the polypeptide.

### Claim 13

A method for identifying a modulator of a polypeptide, the method comprising:
(a) providing the three-dimensional coordinates for a plurality of the amino acids of a polypeptide comprising (1) an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; (2) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; or (3) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 1 or SEQ ID NO: 3 and has at least one biological activity of thymidylate kinase from E. faecalis; such that crystals of the crystallized polypeptide will diffract x-rays to a resolution of 5 Å or better;
(b) identifying a druggable region of the polypeptide; and
(c) selecting at least one potential modulator by using the three dimensional coordinates to determine if a chemical entity may bind to or interfere with the druggable region.

### Claim 14 (depends on 13)

The method of claim 13, wherein the chemical entity is a small molecule.

### Claim 15 (depends on 13)

The method of claim 13, wherein the chemical entity is selected from a database or library of chemical entities.

### Claim 16 (depends on 13)

The method of claim 13, further comprising:
(d) contacting a polypeptide comprising: (1) an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; (2) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; or (3) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 1 or SEQ ID NO: 3 and has at least one biological activity of thymidylate kinase from E. faecalis; and
(e) assaying the activity of the polypeptide after contact with the potential modulator, wherein a change in the activity of the polypeptide indicates that the potential modulator is a modulator of said polypeptide.

### Claim 17

A method for designing a modulator for the prevention or treatment of a E. faecalis related disease or disorder, comprising:
(a) providing the three dimensional structure of a crystallized polypeptide comprising: i) an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; (ii) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; or (iii) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 1 or SEQ ID NO: 3 and has at least one biological activity of thymidylate kinase from E. faecalis; and
(b) designing a potential modulator for the prevention or treatment of a a E. faecalis related disease or disorder by employing the three-dimensional structure in a rational drug design method.

### Claim 18 (depends on 17)

The method of claim 17, further comprising
(c) contacting E. faecalis or a polypeptide comprising i) an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; (ii) an amino acid sequence having at least about 95% identity with the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 4; or (iii) an amino acid sequence encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of a polynucleotide having SEQ ID NO: 1 or SEQ ID NO: 3 and has at least one biological activity of thymidylate kinase from E. faecalis with the potential modulator; and
(d) assaying the activity of the polypeptide or determining the viability of E. faecalis after contact with the modulator, wherein a change in the activity of the polypeptide or the viability of E. faecalis indicates that the modulator may be useful for prevention or treatment of a E. faecalis related disease or disorder.

### Claim 19 (depends on 17)

The method of claim 17, wherein said rational drug design method comprises performing a fitting operation between the structure of a chemical entity and a druggable region of the polypeptide, followed by computationally analyzing the results of the fitting operation to quantify the association between the chemical entity and the druggable region.

### Claim 20 (depends on 17)

The method of claim 17, wherein said rational drug design method comprises determining whether a chemical entity is expected to bind to or interfere with the polypeptide.
